James Essell

Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study

Alison R. Sehgal, Daanish Hoda, Peter A. Riedell et al. · The Lancet Oncology · 2022 · 234 citations

Medicine, Hematology, Oncology +14

Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study

Howard A. Burris, Ian W. Flinn, Manish R. Patel et al. · The Lancet Oncology · 2018 · 205 citations

Medicine, Oncology, Pharmacology +16

Ursodiol Prophylaxis against Hepatic Complications of Allogeneic Bone Marrow Transplantation

James Essell · Annals of Internal Medicine · 1998 · 191 citations

Medicine, Hematology, Pharmacotherapy +17

ROCK2 Inhibition With Belumosudil (KD025) for the Treatment of Chronic Graft-Versus-Host Disease

Madan Jagasia, Aleksandr Lazaryan, Carlos Bachier et al. · Journal of Clinical Oncology · 2021 · 186 citations · Full text

Life Sciences, Immunology, Molecular Medicine +11

Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of <i>FLT3</i>

Mark J. Levis, Mehdi Hamadani, Brent R. Logan et al. · Journal of Clinical Oncology · 2024 · 185 citations · Full text

Medicine, Hematology, Pharmacotherapy +11